Racura Oncology Initiates Phase 1 HARNESS-1 Clinical Trial for Lung Cancer Treatment

Racura Oncology Initiates Phase 1 HARNESS-1 Trial

Racura Oncology Limited, a clinical-stage biopharmaceutical firm based in Sydney, has marked a significant milestone by dosing the first patient in its HARNESS-1 clinical trial. This Phase 1a/b study explores the combination of RC220, a proprietary formulation of (E,E)-bisantrene, with osimertinib for patients diagnosed with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).

Overview of the Trial

The HARNESS-1 trial aims to tackle one of the most pressing challenges in oncology today: TKI (tyrosine kinase inhibitor) resistance. Despite the positive outcomes associated with EGFR TKIs such as osimertinib, many patients eventually experience acquired resistance, necessitating innovative treatment strategies. The trial will evaluate the safety, pharmacokinetics, and early clinical efficacy of RC220 in this context.

The first patient enrolled in the trial received a dose of RC220 at 50 mg/m² through intravenous infusion, with no adverse effects reported so far. This development is a promising step in exploring how RC220 may enhance the effectiveness of existing therapies for lung cancer patients.

Scientific Rationale and Mechanism of Action

EGFR-mutant NSCLC is characterized by persistent EGFR signaling, which initially responds well to EGFR inhibitors. However, as treatment progresses, diverse resistance mechanisms—like secondary EGFR mutations and alternative pathways activation—tend to diminish the effectiveness of these inhibitors. RC220 is specifically designed to target G-quadruplex structures prevalent in oncogenic regulatory regions, potentially disrupting the pathways that lead to tumor progression.

Daniel Tillett, Ph.D., CEO of Racura Oncology, emphasized the importance of this trial, stating, "Dosing the first patient in HARNESS-1 underscores the urgent need to address TKI resistance in EGFR-mutant NSCLC. We are keen to understand if we can effectively target these G4-DNA and RNA structures using RC220 to improve treatment outcomes."

This trial is positioned to not only assess safety but also to gather crucial data on pharmacodynamics and molecular responses related to the treatment. The insights derived could lead to groundbreaking strategies in lung cancer therapy.

Trial Design and Future Steps

HARNESS-1 is structured as a multi-center study incorporating an observational stage using circulating tumor DNA (ctDNA) to identify eligible patients and characterize their tumors before proceeding with treatment. The trial’s Phase 1a will include dose-escalation with three initial cohorts at 50 mg/m², 100 mg/m², and 150 mg/m², followed by evaluations to establish maximum tolerated doses.

Once preliminary safety and pharmacokinetic data has been analyzed, the trial plans to transition into a Phase 1b expansion where an additional 40 patients will further evaluate the combination therapy's efficacy and safety signals.

Looking Ahead

The first patient was treated by Associate Professor Surein Arulananda and his team at Monash Health in Victoria. Racura Oncology plans to open additional study sites to broaden patient recruitment and expedite trial progression. Further details about the HARNESS-1 trial can be accessed via the Australian and New Zealand Clinical Trial Registry.

Racura Oncology remains committed to addressing the significant unmet medical needs of lung cancer patients, with plans to further develop RC220 across various oncology indications. For more information about their ongoing research and initiatives, visit Racura Oncology's website.

By actively pursuing advanced techniques to combat cancer, Racura Oncology represents a hopeful beacon for patients fighting against the odds of resistance in their treatments.